About the Authors

Olivier Nolan-Stevaux

Contributed equally to this work with: Olivier Nolan-Stevaux, Donato Tedesco

oliviern@amgen.com (ONS); dtedesco@cellecta.com (DT)

Affiliation Oncology Research, Amgen, South San Francisco, California, United States of America

Donato Tedesco

Contributed equally to this work with: Olivier Nolan-Stevaux, Donato Tedesco

oliviern@amgen.com (ONS); dtedesco@cellecta.com (DT)

Affiliation Cellecta Inc., Mountain View, California, United States of America

Seamus Ragan

Affiliation Genome Analysis Unit, Amgen, South San Francisco, California, United States of America

Mikhail Makhanov

Affiliation Cellecta Inc., Mountain View, California, United States of America

Alex Chenchik

Affiliation Cellecta Inc., Mountain View, California, United States of America

Astrid Ruefli-Brasse

Affiliation Oncology Research, Amgen, South San Francisco, California, United States of America

Kim Quon

Affiliation Therapeutic Innovation Unit, Amgen, Seattle, Washington, United States of America

Paul D. Kassner

Affiliation Genome Analysis Unit, Amgen, South San Francisco, California, United States of America

Competing Interests

Cellecta, Inc. was a provider of lentiviral shRNA libraries for this study and is the employer of Donato Tedesco, Mikhail Makhanov and Alex Chenchik. Olivier Nolan-Stevaux, Seamus Ragan, Astrid Ruefli-Brasse, Kim Quon and Paul D. Kassner are employed by Amgen. This study was funded by Amgen Inc. There are no further patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

Author Contributions

Conceived and designed the experiments: ONS DT KQ PK. Performed the experiments: ONS DT SR. Analyzed the data: ONS DT SR MM. Contributed reagents/materials/analysis tools: AC. Wrote the paper: ONS DT. Supervised the research program: ARB.